Verona Pharma (VRNA) News Today $22.73 +0.58 (+2.62%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 11:42 AM | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday TradingJuly 25 at 2:00 AM | globenewswire.comVerona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateJuly 23 at 6:12 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Given New $37.00 Price Target at Canaccord Genuity GroupJuly 22, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Increased to $37.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group lifted their price target on Verona Pharma from $35.00 to $37.00 and gave the company a "buy" rating in a research report on Monday.July 19, 2024 | uk.finance.yahoo.comVerona Pharma PLC (I9SA.DU)July 17, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Sets New 52-Week High at $22.55Verona Pharma (NASDAQ:VRNA) Reaches New 52-Week High at $22.55July 17, 2024 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 4.8%July 11, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Sees Strong Trading VolumeVerona Pharma (NASDAQ:VRNA) Sees Large Volume IncreaseJuly 1, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Sees Unusually-High Trading Volume After Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Sees Strong Trading Volume on Analyst UpgradeJune 30, 2024 | seekingalpha.comVerona Pharma Is Launching Ohtuvayre, Although There Will Be CompetitionJune 28, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) PT Raised to $38.00 at Truist FinancialTruist Financial upped their price target on shares of Verona Pharma from $32.00 to $38.00 and gave the company a "buy" rating in a report on Friday.June 27, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Trading Up 5.9% After Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Trading Up 5.9% on Analyst UpgradeJune 27, 2024 | marketbeat.comVerona Pharma Sees Unusually Large Options Volume (NASDAQ:VRNA)Verona Pharma plc (NASDAQ:VRNA - Get Free Report) was the target of some unusual options trading on Thursday. Investors purchased 5,068 call options on the stock. This is an increase of approximately 739% compared to the typical volume of 604 call options.June 27, 2024 | marketbeat.comCanaccord Genuity Group Reiterates Buy Rating for Verona Pharma (NASDAQ:VRNA)Canaccord Genuity Group reissued a "buy" rating and set a $35.00 price objective on shares of Verona Pharma in a research report on Thursday.June 27, 2024 | reuters.comVerona Pharma's inhaled COPD therapy to be priced at $2,950 per monthJune 27, 2024 | marketbeat.comHC Wainwright Increases Verona Pharma (NASDAQ:VRNA) Price Target to $36.00HC Wainwright raised their target price on Verona Pharma from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday.June 26, 2024 | reuters.comUS FDA approves Verona Pharma's therapy for 'smoker's lungs'June 26, 2024 | reuters.comUS FDA approves Verona Pharma's therapy for 'smoker's lungs'June 26, 2024 | globenewswire.comVerona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)June 25, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Sees Large Volume IncreaseVerona Pharma (NASDAQ:VRNA) Sees Large Volume IncreaseJune 22, 2024 | marketbeat.comWellington Management Group LLP Trims Holdings in Verona Pharma plc (NASDAQ:VRNA)Wellington Management Group LLP trimmed its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 15.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,783,994 shares of the company's stock after selling 683,577 shares during the period. WellingJune 20, 2024 | seekingalpha.comVerona Pharma: Next Week's PDUFA Date Ought To Provide An Upside CatalystJune 18, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Down 4.1%Verona Pharma (NASDAQ:VRNA) Trading Down 4.1%June 16, 2024 | marketbeat.comPerceptive Advisors LLC Sells 140,983 Shares of Verona Pharma plc (NASDAQ:VRNA)Perceptive Advisors LLC decreased its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,866,214 shares of the company's stock after selling 14June 13, 2024 | marketbeat.comParkman Healthcare Partners LLC Grows Stock Position in Verona Pharma plc (NASDAQ:VRNA)Parkman Healthcare Partners LLC increased its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 20.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 504,742 shares of the company's stock aftJune 13, 2024 | investors.comWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona StocksJune 12, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Up 8.4%Verona Pharma (NASDAQ:VRNA) Trading 8.4% HigherJune 10, 2024 | marketbeat.comSuperstring Capital Management LP Takes Position in Verona Pharma plc (NASDAQ:VRNA)Superstring Capital Management LP acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 124,040 shares of the company's stock, valued at approximately $2,466,000. Verona Pharma makJune 5, 2024 | marketbeat.comAffinity Asset Advisors LLC Acquires 195,495 Shares of Verona Pharma plc (NASDAQ:VRNA)Affinity Asset Advisors LLC raised its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 53.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 563,824 shares of the company's stock aftMay 31, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Trading Up 4.5%Verona Pharma (NASDAQ:VRNA) Trading Up 4.5%May 29, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 12-Month Low at $11.79Verona Pharma (NASDAQ:VRNA) Hits New 1-Year Low at $11.79May 26, 2024 | marketbeat.comClearbridge Investments LLC Purchases Shares of 248,964 Verona Pharma plc (NASDAQ:VRNA)Clearbridge Investments LLC purchased a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 248,964 shares of the company's stock, valued at appMay 23, 2024 | seekingalpha.comVerona Pharma: Key Inflection Point Directly AheadMay 16, 2024 | marketbeat.comVerona Pharma plc Expected to Post FY2024 Earnings of ($1.36) Per Share (NASDAQ:VRNA)Verona Pharma plc (NASDAQ:VRNA - Free Report) - HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Verona Pharma in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings perMay 15, 2024 | marketbeat.comNicholas Investment Partners LP Trims Position in Verona Pharma plc (NASDAQ:VRNA)Nicholas Investment Partners LP lessened its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 85.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,126 shares of the company's stock after selling 993,863 sharMay 13, 2024 | markets.businessinsider.comStrategic Financing Secures Verona Pharma’s Future Beyond 2026, Ensuring Buy RatingMay 13, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Down 5.8% on Analyst DowngradeVerona Pharma (NASDAQ:VRNA) Shares Down 5.8% on Analyst DowngradeMay 10, 2024 | finance.yahoo.comVerona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic OverviewMay 10, 2024 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deVerona Pharma plc: Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSMay 9, 2024 | globenewswire.comVerona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSMay 6, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Down 4.3% on Insider SellingVerona Pharma (NASDAQ:VRNA) Stock Price Down 4.3% on Insider SellingMay 5, 2024 | insidertrades.comKathleen A. Rickard Sells 36,248 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 3, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Kathleen A. Rickard Sells 36,248 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) insider Kathleen A. Rickard sold 36,248 shares of the firm's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total transaction of $71,046.08. Following the sale, the insider now owns 2,621,552 shares of the company's stock, valued at $5,138,241.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 2, 2024 | globenewswire.comVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024April 27, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) is Vivo Capital LLC's 6th Largest PositionVivo Capital LLC lowered its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 15.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,610,177 shares of the company's stock after sellinApril 25, 2024 | marketbeat.comJennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA)Jennison Associates LLC grew its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,585,385 shares of the company's stock afterApril 25, 2024 | investing.comVerona Pharma shares target raised on COPD launch outlook Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New trading system called MSFT, NVDA & MSFT (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today. Just follow this link here! VRNA Media Mentions By Week VRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼0.490.62▲Average Medical News Sentiment VRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼62▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: JAZZ News ELAN News SMMT News VKTX News CYTK News MDGL News BBIO News NUVL News OGN News APLS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
